Investigator |
Title |
Sponsor |
ID |
Dates |
Amount |
Michael J Absalon, MDPHD |
Understanding Chemotherapy Failure in AML: Resistance Mechanisms to a Nanoparticle Chemotherapy Delivery System |
Cancer Free Kids |
Absalon/Grimes_Cance |
12/01/2017 - 11/30/2018 |
$50,000 |
Biplab DasGupta, PhD |
Targeting Tumor Metabolism in Diffuse Intrinsic Pontine Glioma (DIPG) cells. |
Cancer Free Kids |
Dasgupta, B, CFK |
07/01/2017 - 06/30/2019 |
$50,000 |
Biplab DasGupta, PhD |
Biguanide Sensitivity of Glioma Stem Cells |
National Institutes of Health |
R01 NS099162 |
02/01/2016 - 11/30/2021 |
$347,104 |
Biplab DasGupta, PhD |
Repurposing an FDA-approved Drug for acne to treat Glioblastoma |
University of Cincinnati |
MTP Pilot |
12/01/2017 - 11/30/2018 |
$50,000 |
Biplab DasGupta, PhD |
Exploring Therapeutic Vulnerability of Passenger Alterations in Glioblastoma |
University of Cincinnati Cancer Center |
CCC -Bridge |
02/01/2018 - 01/31/2019 |
$15,000 |
Peter Matthew Kennedy de Blank, MD |
Rapid Quantitative MR for Disease Assessment in Pediatric Brain Tumors |
St. Baldrick's Foundation |
527540 |
07/01/2017 - 06/30/2019 |
$115,000 |
Peter Matthew Kennedy de Blank, MD |
Radiographic Biomarkers and Functional Outcomes of Vision in Optic Pathway Gliomas |
The Dana Foundation |
de blank, P., Dana |
04/20/2017 - 04/19/2019 |
$148,118 |
Rachid Drissi, PhD |
BMI-1 as a Novel Therapeutic Target to Treat Diffuse Intrinsic Pontine Glioma |
Cancer Free Kids |
Drissi, Rachid, CFK |
07/01/2017 - 06/30/2019 |
$50,000 |
Rachid Drissi, PhD |
Evaluating the Role of BMI-1 in Diffuse Intrinsic Pontine Glioma |
Pray Hope Believe Foundation |
Drissi_PHB Foundation |
01/01/2018 - 12/31/2018 |
$45,614 |
Maryam Fouladi, MD |
CONNECT |
Curing Kids Cancer |
CKC, Fouladi, Maryam |
01/01/2018 - 12/31/2020 |
$50,000 |
Maryam Fouladi, MD |
COG NCTN Network Group Operations Center |
National Institutes of Health (Children's Hospital of Philadelphia) |
U10 CA180886 |
04/11/2014 - 02/28/2019 |
$7,499 |
Maryam Fouladi, MD |
Central Nervous System Tumor Committee |
National Institutes of Health (Children's Hospital of Philadelphia) |
U10 CA180886 |
07/01/2016 - 02/28/2019 |
$37,500 |
Maryam Fouladi, MD |
Pediatric Brain Tumor Consortium (PBTC) |
National Institutes of Health (St Jude's Children's Hospital) |
UM1 CA081457 |
04/01/2014 - 03/31/2019 |
$94,892 |
Maryam Fouladi, MD |
|
National Institutes of Health (St Jude's Children's Hospital) |
CA081457 |
UM104/01/2014 - 03/31/2019 |
$39,000 |
Maryam Fouladi, MD |
Establishment of an International Diffuse Intrinsic Pontine Glioma (DIPG) Registry |
The Cure Starts Now Foundation |
DIPG - Fouladi |
01/01/2012 - 12/31/2018 |
$233,311 |
Maryam Fouladi, MD |
International Collaborative Network for Neurooncology Clinical Trials (CONNECT) |
The Cure Starts Now Foundation |
Fouladi, M, CSNF |
10/01/2017 - 09/30/2020 |
$615,162 |
James Geller, MD |
NIH COG Phase 1 Study Chair |
National Institutes of Health (Children's Hospital of Philadelphia) |
UM1 CA097452 |
08/01/2012 - 07/31/2018 |
$7,500 |
Harry Leighton Grimes, PhD |
12th International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia |
Taub Foundation Program for MDS Research |
Grimes, L., Taub |
10/01/2017 - 09/30/2018 |
$40,000 |
Adrienne Hammill, MD |
Brain Vascular Malformation Consortium: Predictors of Clinical Course |
National Institutes of Health (The Regents of the Univ of California) |
U54 NS065705 |
09/30/2014 - 07/31/2019 |
$16,318 |
Benjamin Mizukawa, MD |
Precision Medicine in a Pediatric Leukemia Avatar System |
St. Baldrick's Foundation |
CDA |
07/01/2016 - 06/30/2018 |
$115,000 |
Robin E Norris, MD, MPH |
Evaluating Cdk5 and TGF-ß Inhibitors for the Treatment of Childhood Cancer |
St. Baldrick's Foundation |
422667 |
08/01/2017 - 06/30/2018 |
$70,026 |
Maureen O'Brien, MD |
Scientific Advisor Board Service |
Alex's Lemonade Stand Foundation |
O'Brien, Maureen ALS |
12/01/2017 - 11/30/2018 |
$10,000 |
Maureen O'Brien, MD |
T2016-003: Epigenetic Reprogramming in Relapse AML: a Phase I study |
Children's Hospital Los Angeles |
T2016003 |
12/01/2017 - 11/30/2021 |
$48,001 |
John P Perentesis, MD |
COG NCORP Research Base: Per case Reimbursement |
National Institutes of Health (Children's Hospital of Philadelphia) |
UG1 CA189955 |
08/01/2014 - 07/31/2018 |
$25,000 |
John P Perentesis, MD |
CHOP/COG ALTE15N2 LEAHRN (late effects after high-risk Neuroblastoma) |
St. Baldrick's Foundation (Children's Hospital of Philadelphia) |
ALTE15N2 |
03/01/2018 - 02/28/2022 |
$8,250 |
Lisa Marie Privette Vinnedge, PhD |
Exploring the Role of the Oncogene Dek as a Novel Player in Alzheimer’s Disease |
Life Sciences Research Foundation (University of Cincinnati) |
life2016 |
09/01/2016 - 08/31/2018 |
$18,032 |
Lisa Marie Privette Vinnedge, PhD |
Mechanisms Coupling DEK to Oncogenesis |
National Institutes of Health |
R01 CA218072 |
02/08/2018 - 01/31/2023 |
$363,713 |
Lisa Marie Privette Vinnedge, PhD |
Investigating DEK as a prognostic marker for secondary breast cancer in female survivors of pediatric Hodgkin’s Lymphoma |
University of Cincinnati Cancer Center |
UCCI2018 |
03/01/2018 - 02/28/2019 |
$50,000 |
Sonya Ruiz-Torres |
Role of the Fanconi Anemia DNA Repair Pathway in Epidermal Stem and Progenitor Cells and Squamous Cell Carcinoma |
National Institutes of Health |
F31 AR070008 |
09/01/2016 - 08/31/2019 |
$37,176 |
Anthony J Sabulski, MD |
Chemotherapy Treatment in PDX Leukemia Avatars will pressure outgrowth of leukemic clones relevant to patient relapsed or refractory disease |
American Society of Hematology |
HONORS |
07/01/2017 - 06/30/2018 |
$5,000 |
Elizabeth K Schorry, MD |
DOD Neurofibromatosis Clinical Consortium Award |
Department of Defense (University of Alabama-Birmingham) |
W81XWH1720037 |
08/15/2017 - 08/14/2018 |
$2,501 |
Kanimozhi Vairamani, PhD |
Training Grant (NIEH) |
National Institutes of Health (University of Cincinnati) |
1013581 |
09/01/2017 - 08/31/2019 |
$40,180 |
Brian D Weiss, MD |
A Phase I/II Study of the Mitogen Activated Protein Kinase (MEK) 1 Inhibitor Selumetinib in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) |
Johns Hopkins School of Medicine |
2002883540 |
01/01/2016 - 12/31/2018 |
$249,577 |
Brian D Weiss, MD |
A Phase I/II Study of the Mitogen Activated Protein Kinase (MEK) 1 Inhibitor Selumetinib in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) |
Johns Hopkins School of Medicine |
2001824052 |
01/01/2016 - 12/31/2018 |
$137,500 |
Total Annual Grant Award Dollars |
$3,191,974 |